

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.

Listing of Claims

1-14. (Cancelled)

15. (Previously presented) A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said cellular proliferative disease, wherein said cellular proliferative disease is a solid tumor.

16. (Previously presented) A method according to claim 1 wherein said amonafide is administered before the administration of said homoharringtonine.

17. (Previously presented) A method according to claim 1 wherein said amonafide is administered during the administration of said homoharringtonine.

18. (Previously presented) A method according to claim 1 wherein said amonafide is administered after the administration of said homoharringtonine.

19. (Previously presented) The method according to claim 1 wherein said anticancer effect of said amonafide and said homoharringtonine on said cellular proliferative disease is greater than that for said amonafide or said homoharringtonine alone.

20. (Canceled)

21. (Canceled)

22. (Previously presented) The method according to claim 21 wherein said anticancer effect is a chemopotentiating effect.

23. (Previously presented) The method according to claim 21 wherein said anticancer effect is a cytostatic effect on increase in tumor volume quadrupling time.

24. (Previously presented) The method according to claim 21 wherein said anticancer effect is an increase in tumor volume quadrupling time.

25. (Previously presented) A composition comprising amonafide and homoharringtonine, wherein the modulation of a cellular proliferative disease by amonafide and homoharringtonine is greater than that for amonafide or homoharringtonine alone.

26. (New) A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said cellular proliferative disease, wherein said cellular proliferative disease is a solid tumor, and wherein the treatment with amonafide in conjunction with homoharringtonine is more effective than the treatment with homoharringtonine alone.

27. (New) A method of increasing the chemotherapeutic effectiveness of homoharringtonine comprising administering to a patient afflicted with a homoharringtonine sensitive tumor, homoharringtonine in conjunction with amonafide each in an amount sufficient to have an anticancer effect on said tumor, wherein treatment with homorarringtonine in conjunction with amonafide is more effective than the treatment with homoharringtonine alone.

28. (New) A method of treatment of a host with a homoharringtonine sensitive solid tumor, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said solid tumor, and wherein treatment with amonafide in conjunction with homoharringtonine is more effective than treatment with homoharringtonine alone.

29. (New) A method of increasing the chemotherapeutic effectiveness of amonafide comprising administering to a patient afflicted with an amonafide sensitive tumor, homoharringtonine in conjunction with amonafide each in an amount sufficient to have an anticancer effect on said tumor, wherein treatment with homorarringtonine in conjunction with amonafide is more effective than the treatment with amonaafide alone.

30. (New) A method of treatment of a host with an amonafide sensitive solid tumor, comprising contacting said host with amonafide in conjunction with homoharringtonine, each in an amount sufficient to have an anticancer effect on said solid tumor, and wherein treatment with amonafide in conjunction with homoharringtonine is more effective than treatment with amonafide alone.